ProCE Banner Activity

TROPION-PanTumor01: Phase I Dose Analysis of Datopotamab Deruxtecan, a Novel TROP2-Targeted ADC, in Pretreated Advanced NSCLC

Slideset Download
Conference Coverage
Phase I results from TROPION-PanTumor01 suggest durable antitumor activity and a manageable safety profile with datopotamab deruxtecan in patients with previously treated advanced NSCLC.

Released: June 08, 2021

Expiration: June 07, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme